NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

This clinical trial aims to evaluate the effectiveness of a new treatment approach for patients with stage III or IV melanoma that has spread to other parts of the body but can still be surgically removed. The study combines two treatments: LTX-315 and pembrolizumab. Melanoma that has spread to other parts of the body can often be treated with surgery. Despite surgery, there is a high risk of the cancer coming back. Pembrolizumab, an immune checkpoint inhibitor, can reduce this risk when given after surgery. Recent studies have shown that giving pembrolizumab before surgery, along with post-s

Trial Details

NCT ID
NCT06651151
Phase
PHASE2
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • LTX-315 + pembrolizumab
Locations (sample)
  • Oslo, Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • Participant must be 18 years of age inclusive, at the time of signing the informed consent.
  • Histologically confirmed, clinically detectable stage III-IV(M1a) melanoma, judged fully resectable and eligible for neoadjuvant treatment by conse…
  • Measurable disease as per RECIST version 1.1 criteria.
  • Judged medically fit to undergo the planned surgery by the surgical team.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →